Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

Distribution expansion

10 Mar 2009 07:00

RNS Number : 5744O
LiDCO Group Plc
10 March 2009
 



Press Release 

10th March 2009

LiDCO Group Plc

("LiDCO" or the "Company")

Distribution Expansion in Germany

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce further expansion of its distribution network. The Company has signed a distribution agreement for the sale of its LiDCOrapid Monitor and disposables in Germany with Absolute Medical GmbH & Co. KG based in RatingenGermany. With LiDCO's existing north German distribution partner, the agreement gives LiDCO access to the biggest hemodynamic monitoring market in Europe.

With a population of 82 million people, Germany ranks as the third largest medical device market in the world (behind the USA and Japan) and represents 36% by value of the European medical device marketAt around 10.6% of GDP, healthcare expenditure in Germany is currently at a high level creating a demand for sophisticated medical equipment which has demonstrated significant improvements in clinical outcome.

Absolute Medical was recently founded by Bradley Gould an experienced CEO with 28 years of experience in the global medical device industry. Absolute Medical's focus is on sales and distribution of advanced medical devices in Germany to hospital acute care, critical care and anaesthesia departments. 

Absolute Medical's CEO Mr Bradley Gould commented "We are very excited to have the opportunity to introduce this new technology to the largest European hemodynamic monitoring market. We have great belief in LiDCO's products and are confident that with our deep knowledge of the hemodynamic monitoring market in Germany, we expect to have great success marketing the LiDCOrapid.

Dr Terry O'Brien, CEO LiDCO Group plc, commented:  "We are delighted to have further broadened our distribution, which means we now have sales reach to the majority of EuropeThe LiDCOrapid is an innovative solution that provides a cost effective, highly accurate solution for monitoring high-risk surgical patients. Working with two distribution partners in Germany means that LiDCO now has full access to the biggest medical device market in Europe."

- ENDS - 

For more information please contact:

LiDCO Group Plc

Terry O'Brien - Chief Executive

John Rowland - Company Secretary

Tel: +44 (0)20 7749 1500

www.lidco.com 

Panmure Gordon and Co

Edward Farmer/ Katherine Roe

+44 (0)20 7459 3600

www.panmure.com 

Media enquiries

Abchurch Communications

Heather Salmond / Stephanie Cuthbert / Simone Alves

+44 (0)20 7398 7728

simone.alves@abchurch-group.com 

www.abchurch-group.com 

About LiDCO Group Plc

LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's manufacturing facility is in Hoxton, London and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid volume (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery. 

Early and rapid warning of change

Clear indication of therapeutic route: fluid or drug

Quantification of hemodynamic response, particularly stroke volume

Permits more effective delivery of fluids - the right amount at the right time

Advanced hemodynamic care has been shown to:

- Contribute to reduced morbidity and complications

- Reduce length of stay

- Reduce overall cost of care

* LiDCO single patient use disposables used in conjunction with the LiDCOplus and LiDCOrapid Monitors. 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase

* LiDCOlive: a software product in development for the remote display of hemodynamic monitoring parameters derived through use of the LiDCOplus or LiDCOrapid monitors

LiDCO Distribution Network:

The Company sells direct in the UK, direct and elsewhere through a worldwide network of speciality critical care and anesthesia distributors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGGGFNLNGLZM
Date   Source Headline
14th Feb 20181:15 pmRNSHolding(s) in Company
1st Feb 20187:00 amRNSBlock Listing Review
17th Jan 20187:00 amRNSJapan registration &appointment of new distributor
15th Jan 201810:06 amRNSHolding(s) in Company
13th Dec 20174:33 pmRNSHolding(s) in Company
22nd Nov 20179:28 amRNSHolding(s) in Company
10th Oct 20177:00 amRNSHalf-year Report
10th Aug 20177:01 amRNSTrading update & Notice of results
10th Aug 20177:00 amRNSFirst High Usage Programme Account in US
1st Aug 20177:00 amRNSBlock Listing Review
25th Jul 20174:37 pmRNSHolding(s) in Company
6th Jul 20177:00 amRNSConfirmation of CFO appointment & Award of options
8th Jun 20177:00 amRNSInvestor presentation
7th Jun 20177:00 amRNSUS FDA clearance for LiDCOunity v2
10th May 201711:35 amRNSResult of AGM
10th May 20177:00 amRNSAGM Statement
9th May 20177:00 amRNSNew LiDCOunity v2 monitor launch
4th May 20177:00 amRNSLaunch of new website
28th Apr 20177:00 amRNSHolding(s) in Company
20th Apr 20177:00 amRNSAward of share options/ director dealing
3rd Apr 20177:00 amRNSInvestor presentation
3rd Apr 20177:00 amRNSDirector/PDMR Shareholding
28th Mar 20177:00 amRNSFinal Results
13th Mar 20177:00 amRNSNotice of Results
1st Mar 20177:00 amRNSBoard Changes
16th Feb 201710:07 amRNSHolding(s) in Company
14th Feb 20177:00 amRNSTrading update and notice of results
3rd Feb 20177:00 amRNSHolding(s) in Company
19th Jan 201710:29 amRNSHoldings in Company
18th Jan 20177:00 amRNSHolding(s) in Company
10th Jan 20177:00 amRNSAppointment of Head of North America
3rd Jan 20171:03 pmRNSHolding(s) in Company
3rd Jan 201712:31 pmRNSHolding(s) in Company
3rd Jan 201712:30 pmRNSHolding(s) in Company
23rd Dec 201610:23 amRNSResult of GM, TVR and Transactions by PDMRs
7th Dec 20167:00 amRNSProposed Placing & Notice of General Meeting
11th Oct 20167:00 amRNSHalf-year Report
20th Sep 20167:00 amRNSNotice of Results
8th Sep 20167:00 amRNSFurther clinical support for LiDCOrapid
7th Sep 20163:46 pmRNSHolding(s) in Company
11th Aug 20167:01 amRNSAppointment of Non Executive Director
11th Aug 20167:00 amRNSTrading update and notice of results
1st Jun 20169:17 amRNSHolding(s) in Company
25th May 201612:28 pmRNSResult of AGM
25th May 20167:00 amRNSAGM Statement
16th May 20167:00 amRNSUS Distribution Agreement with ICU Medical
6th May 20167:00 amRNSNotice of AGM
21st Apr 20167:00 amRNSUS launch of new LiDCOunity monitor
4th Apr 20167:00 amRNSUS FDA 510k clearance for LiDCOunity
30th Mar 201611:23 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.